Protein hydrolysate/leucine co-ingestion reduces the prevalence of hyperglycemia in type 2 diabetic patients.
Manders
Ralph J F
RJ
Department of Human Biology, Maastricht University, P.O. Box 616, 6200 MD Maastricht, Netherlands. r.manders@hb.unimaas.nl
Praet
Stephan F E
SF
Meex
Ruth C R
RC
Koopman
René
R
de Roos
André L
AL
Wagenmakers
Anton J M
AJ
Saris
Wim H M
WH
van Loon
Luc J C
LJ
D000284:Administration, Oral; D000328:Adult; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D002940:Circadian Rhythm; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D006801:Humans; D006943:Hyperglycemia / Q000453:epidemiology* / Q000517:prevention & control*; D007930:Leucine / Q000008:administration & dosage / Q000627:therapeutic use*; D015995:Prevalence; D011492:Protein Hydrolysates / Q000008:administration & dosage / Q000627:therapeutic use*; D012016:Reference Values
D001786:Blood Glucose; D011492:Protein Hydrolysates; D007930:Leucine